Oxford Finance provided a $60 million senior secured term loan for RxSight, a privately-held MedTech company that commercialized an FDA-approved adjustable intraocular lens that can be customized after cataract surgery. The funds will be used for general working capital, including sales, marketing, research and development.
“RxSight’s proprietary Light Adjustable Lens offers an invaluable advancement in the cataract surgery market,” Christopher A. Herr, senior managing director at Oxford Finance, said. “Oxford is happy to provide capital to support the company’s innovative approach that enables optimization of vision specific to a patient’s needs.”
Today, approximately 100 U.S. surgeons are using the Light Adjustable Lens to deliver customized vision for their cataract patients.
“We are delighted to have partnered with Oxford Finance for additional funding to fuel continued commercial expansion and technology innovations for the premium cataract surgery market,” Shelley Thunen, CFO at RxSight, said.
